Journal
ONCOIMMUNOLOGY
Volume 5, Issue 4, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1115178
Keywords
Clinical NK cell studies; ex vivo expansion; manufacturing of NK cell products; quality control
Categories
Funding
- European Union [317013, 602366]
- St Baldrick's Foundation in USA
- UK Leukemia Lymphoma Research
- German Ministry of Education (IFB-Tx) [01E00802]
- NATIONAL CANCER INSTITUTE [P01CA065493, P30CA077598] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013-2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available